526 related articles for article (PubMed ID: 33685991)
1. Genomic Alterations in
Cai Y; Xu G; Wu F; Michelini F; Chan C; Qu X; Selenica P; Ladewig E; Castel P; Cheng Y; Zhao A; Jhaveri K; Toska E; Jimenez M; Jacquet A; Tran-Dien A; Andre F; Chandarlapaty S; Reis-Filho JS; Razavi P; Scaltriti M
Cancer Res; 2021 May; 81(9):2470-2480. PubMed ID: 33685991
[TBL] [Abstract][Full Text] [Related]
2. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.
Elkabets M; Vora S; Juric D; Morse N; Mino-Kenudson M; Muranen T; Tao J; Campos AB; Rodon J; Ibrahim YH; Serra V; Rodrik-Outmezguine V; Hazra S; Singh S; Kim P; Quadt C; Liu M; Huang A; Rosen N; Engelman JA; Scaltriti M; Baselga J
Sci Transl Med; 2013 Jul; 5(196):196ra99. PubMed ID: 23903756
[TBL] [Abstract][Full Text] [Related]
3. PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition.
Castel P; Ellis H; Bago R; Toska E; Razavi P; Carmona FJ; Kannan S; Verma CS; Dickler M; Chandarlapaty S; Brogi E; Alessi DR; Baselga J; Scaltriti M
Cancer Cell; 2016 Aug; 30(2):229-242. PubMed ID: 27451907
[TBL] [Abstract][Full Text] [Related]
4. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
5. Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.
Leroy C; Ramos P; Cornille K; Bonenfant D; Fritsch C; Voshol H; Bentires-Alj M
Breast Cancer Res; 2016 Apr; 18(1):41. PubMed ID: 27048245
[TBL] [Abstract][Full Text] [Related]
6. Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations.
Varkaris A; Fece de la Cruz F; Martin EE; Norden BL; Chevalier N; Kehlmann AM; Leshchiner I; Barnes H; Ehnstrom S; Stavridi AM; Yuan X; Kim JS; Ellis H; Papatheodoridi A; Gunaydin H; Danysh BP; Parida L; Sanidas I; Ji Y; Lau K; Wulf GM; Bardia A; Spring LM; Isakoff SJ; Lennerz JK; Del Vecchio K; Pierce L; Pazolli E; Getz G; Corcoran RB; Juric D
Cancer Discov; 2024 Feb; 14(2):227-239. PubMed ID: 37916958
[TBL] [Abstract][Full Text] [Related]
7. AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.
Dunn S; Eberlein C; Yu J; Gris-Oliver A; Ong SH; Yelland U; Cureton N; Staniszewska A; McEwen R; Fox M; Pilling J; Hopcroft P; Coker EA; Jaaks P; Garnett MJ; Isherwood B; Serra V; Davies BR; Barry ST; Lynch JT; Yusa K
Oncogene; 2022 Nov; 41(46):5046-5060. PubMed ID: 36241868
[TBL] [Abstract][Full Text] [Related]
8. CD44/HA signaling mediates acquired resistance to a PI3Kα inhibitor.
Yang C; Sheng Y; Shi X; Liu Y; He Y; Du Y; Zhang G; Gao F
Cell Death Dis; 2020 Oct; 11(10):831. PubMed ID: 33024087
[TBL] [Abstract][Full Text] [Related]
9. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
Ippen FM; Grosch JK; Subramanian M; Kuter BM; Liederer BM; Plise EG; Mora JL; Nayyar N; Schmidt SP; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
Neuro Oncol; 2019 Nov; 21(11):1401-1411. PubMed ID: 31173106
[TBL] [Abstract][Full Text] [Related]
10. Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition.
Yoon SO; Shin S; Karreth FA; Buel GR; Jedrychowski MP; Plas DR; Dedhar S; Gygi SP; Roux PP; Dephoure N; Blenis J
Mol Cell; 2017 Aug; 67(3):512-527.e4. PubMed ID: 28757207
[TBL] [Abstract][Full Text] [Related]
11. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
[TBL] [Abstract][Full Text] [Related]
12. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
13. Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer.
Nunnery SE; Mayer IA
Drugs; 2020 Nov; 80(16):1685-1697. PubMed ID: 32894420
[TBL] [Abstract][Full Text] [Related]
14. AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
Guichard SM; Curwen J; Bihani T; D'Cruz CM; Yates JW; Grondine M; Howard Z; Davies BR; Bigley G; Klinowska T; Pike KG; Pass M; Chresta CM; Polanska UM; McEwen R; Delpuech O; Green S; Cosulich SC
Mol Cancer Ther; 2015 Nov; 14(11):2508-18. PubMed ID: 26358751
[TBL] [Abstract][Full Text] [Related]
15. Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER
Ros S; Wright AJ; D'Santos P; Hu DE; Hesketh RL; Lubling Y; Georgopoulou D; Lerda G; Couturier DL; Razavi P; Pelossof R; Batra AS; Mannion E; Lewis DY; Martin A; Baird RD; Oliveira M; de Boo LW; Linn SC; Scaltriti M; Rueda OM; Bruna A; Caldas C; Brindle KM
Cancer Cell; 2020 Oct; 38(4):516-533.e9. PubMed ID: 32976773
[TBL] [Abstract][Full Text] [Related]
16. A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3Kα inhibition in controlling tumor growth.
Ruicci KM; Meens J; Sun RX; Rizzo G; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Boutros PC; Ailles L; Nichols AC
Int J Cancer; 2019 Oct; 145(8):2100-2106. PubMed ID: 30468243
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.
Beaver JA; Gustin JP; Yi KH; Rajpurohit A; Thomas M; Gilbert SF; Rosen DM; Ho Park B; Lauring J
Clin Cancer Res; 2013 Oct; 19(19):5413-22. PubMed ID: 23888070
[TBL] [Abstract][Full Text] [Related]
18. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
Fujimoto Y; Morita TY; Ohashi A; Haeno H; Hakozaki Y; Fujii M; Kashima Y; Kobayashi SS; Mukohara T
Sci Rep; 2020 Dec; 10(1):21762. PubMed ID: 33303839
[TBL] [Abstract][Full Text] [Related]
19. PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors.
Tateishi K; Nakamura T; Juratli TA; Williams EA; Matsushita Y; Miyake S; Nishi M; Miller JJ; Tummala SS; Fink AL; Lelic N; Koerner MVA; Miyake Y; Sasame J; Fujimoto K; Tanaka T; Minamimoto R; Matsunaga S; Mukaihara S; Shuto T; Taguchi H; Udaka N; Murata H; Ryo A; Yamanaka S; Curry WT; Dias-Santagata D; Yamamoto T; Ichimura K; Batchelor TT; Chi AS; Iafrate AJ; Wakimoto H; Cahill DP
Clin Cancer Res; 2019 Jul; 25(14):4375-4387. PubMed ID: 30975663
[TBL] [Abstract][Full Text] [Related]
20. Cell Line-Specific Network Models of ER
Gómez Tejeda Zañudo J; Mao P; Alcon C; Kowalski K; Johnson GN; Xu G; Baselga J; Scaltriti M; Letai A; Montero J; Albert R; Wagle N
Cancer Res; 2021 Sep; 81(17):4603-4617. PubMed ID: 34257082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
